

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

BRISTOL-MYERS SQUIBB CO.,)
E. R. SQUIBB & SONS, L.L.C.,)
ONO PHARMACEUTICAL CO., LTD., and)
TASUKU HONJO,)
)
Plaintiffs,)
)
v.)
)
MERCK & CO., INC. and)
MERCK SHARP & DOHME CORP.,)
)
Defendants.)
_____)

C.A. No. _____

JURY TRIAL DEMANDED

COMPLAINT

Plaintiffs Bristol-Myers Squibb Co. (“BMS”), E. R. Squibb & Sons, L.L.C. (“Squibb”), Ono Pharmaceutical Co., Ltd. (“Ono”), and Tasuku Honjo (collectively “Plaintiffs”), for their complaint for patent infringement against Defendants Merck & Co., Inc. and Merck Sharp & Dohme Corp. (collectively “Defendants” or “Merck”), hereby allege as follows:

INTRODUCTION

1. According to the American Cancer Society, more than one million people in the United States are diagnosed with cancer each year (<http://www.cancer.org/cancer/index>). Cancer is a disease that results from the uncontrolled proliferation of cells that were once normal but have transformed into cancerous cells. Although a human’s natural immune system has the potential to eliminate cancerous cells, cancer cells have the ability to “turn off” the immune system thus allowing the cancer cells to continue to grow unchecked.

2. Melanoma is a type of cancer that begins in the melanocytes, the cells that produce the pigment that colors skin, hair, and eyes (<http://www.melanoma.org/understand->

melanoma/what-is-melanoma). Metastatic melanoma, also known as advanced melanoma, or Stage IV melanoma, is a melanoma that has spread to other parts of the body

(<http://www.melanoma.org/understand-melanoma/what-is-melanoma/metastatic-melanoma>).

Late stage melanoma is one of the most aggressive forms of cancer; when diagnosed in the late stages, the average survival rate is only six months, with a one year survival rate of 25.5%

(<http://news.bms.com/press-release/bristol-myers-squibb-receives-accelerated-approval-opdivo-nivolumab-us-food-and-drug-a>).

3. This case relates to a groundbreaking type of cancer treatment called “immunotherapy.” Treating cancer using immunotherapy is a scientific breakthrough and has the potential to revolutionize cancer treatment by using a patient’s own immune system to eliminate cancer cells.

4. T cells are an important part of the human immune system. In addition to eliminating foreign matter such as bacteria and viruses from a human body, they also help remove cancerous cells in the body. T cells carry a protein called PD-1 on their surface. PD-1 serves as an immune system checkpoint, shutting down the T cells’ activity at the appropriate time to prevent an overactive immune response. Cancer cells can exploit the PD-1 protein’s ability to trigger the immune checkpoint. When the PD-1 is triggered in this way, it shuts down or decreases the T cells’ activity of removing the unwanted cancer cells from the body. Thus, the triggering of the PD-1 checkpoint can prevent a patient’s immune system from destroying the cancer cells.

5. The invention at issue here covers using antibodies that bind to PD-1 (“anti-PD-1 antibodies”) in a method for treating metastatic melanoma. By binding to PD-1 and blocking the

PD-1 checkpoint pathway, the anti-PD-1 antibodies allow a patient's immune system to resume its ability to recognize, attack, and destroy cancer cells.

6. The Plaintiffs put this scientific breakthrough into practice by developing an anti-PD-1 antibody called nivolumab, the first anti-PD-1 antibody approved anywhere in the world for cancer treatment.

7. Merck is threatening to exploit, and is exploiting, that invention with a later-developed anti-PD-1 antibody. As described below, Merck is preparing to infringe, and is infringing, plaintiffs' patent for methods of treating cancer with anti-PD-1 antibodies.

PARTIES

8. BMS is a corporation organized under the laws of the state of Delaware, with a principal place of business at 345 Park Ave., New York, New York 10154. E. R. Squibb & Sons, L.L.C., is a limited liability company organized and existing under the laws of the state of Delaware, with its principal place of business at Route 206 & Province Line Road, Princeton, New Jersey 08543. Ono is a corporation organized under the laws of Japan, with a place of business at 8-2 Kyutaromachi 1-chome, Chuo-ku, Osaka 541-8654, Japan. Tasuku Honjo is an individual with a place of business at Kyoto University, Graduate School of Medicine, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan.

9. On information and belief, Defendant Merck & Co., Inc. is a corporation incorporated under the laws of the state of New Jersey with a place of business at 2000 Galloping Hill Rd., Kenilworth, New Jersey, 07053. On information and belief, Defendant Merck Sharp & Dohme Corp. is a subsidiary of Merck & Co., Inc., and is a corporation incorporated under the laws of the state of New Jersey with a place of business at 2000 Galloping Hill Rd., Kenilworth, New Jersey, 07053.

JURISDICTION AND VENUE

10. This is an action for patent infringement arising under the Patent Laws of the United States, 35 U.S.C. § 271 et seq.

11. This Court has subject matter jurisdiction over this action pursuant to 28 U.S.C. §§ 1331 and 1338.

12. This Court has personal jurisdiction over both Defendants because they are registered with the Delaware Department of State to transact business in Delaware and, upon information and belief, have systematic and continuous contacts in Delaware, do regularly transact business in Delaware, have derived substantial revenue from sales of pharmaceutical products in Delaware, and currently market their anti-PD-1 antibody product pembrolizumab for the treatment of metastatic melanoma in Delaware. On information and belief, Defendants have repeatedly availed themselves of the Delaware Courts.

13. Defendants reside in this judicial district and venue is proper in this district under 28 U.S.C. §§ 1391(b), (c), and/or 1400(b).

INVENTION OF METHODS FOR TREATING CANCER

14. On July 7, 2015, the United States Patent & Trademark Office (“USPTO”) duly and legally issued United States Patent No. 9,073,994 (the “994 patent” (Exhibit 1)) titled “Immunopotentiative Composition.” The inventors of the 994 patent showed for the first time that anti-PD-1 antibodies were useful in methods to treat cancer. Tasuku Honjo is a co-inventor and original co-assignee of the 994 patent. Ono is an original co-assignee and exclusive licensor of BMS under the 994 patent. BMS and Squibb are each exclusive licensees of one or more exclusionary rights under the 994 patent. The 994 patent claims methods for treating cancer with an antibody against PD-1.

15. Plaintiffs have put the invention of the 994 patent into practice by developing the breakthrough biologic drug nivolumab. Nivolumab is a monoclonal antibody that recognizes and binds to the PD-1 protein. When nivolumab binds to the PD-1 protein, that PD-1 protein cannot interact with its natural binding partners. Using nivolumab to block the interaction between PD-1 and its binding partners allows a more robust T cell response by the patient's own immune system.

16. Clinical testing of nivolumab confirms the remarkable promise of anti-PD-1 immunotherapy. After rigorous worldwide testing, on July 4, 2014, nivolumab became the first anti-PD-1 antibody approved anywhere in the world for treating cancer, when Japanese regulatory authorities approved nivolumab for the treatment of melanoma. On December 22, 2014, the FDA approved nivolumab for treatment of advanced melanoma in the United States.

17. Plaintiffs have continued worldwide development of nivolumab for treatment of a broad range of cancers, including non-small cell lung cancer, renal cell carcinoma, head and neck cancer, glioblastoma, and non-Hodgkin lymphoma.

18. In Phase III clinical testing, patients with advanced melanoma who received nivolumab showed superior overall survival compared to those who did not, leading BMS to stop the clinical study early and make nivolumab available to all patients in the trial (<http://news.bms.com/press-release/phase-3-first-line-melanoma-study-nivolumab-investigational-pd-1-checkpoint-inhibitor->). Based on, *inter alia*, those clinical results, BMS submitted, and on September 26, 2014, the FDA accepted, a biologics license application ("BLA") for nivolumab in the United States for certain melanoma patients (<http://news.bms.com/press-release/bristol-myers-squibb-announces-multiple-regulatory-milestones-opdivo-nivolumab-us-and->). On December 22, 2014, the FDA approved nivolumab

for treatment of advanced melanoma in the United States. Since that date, BMS has marketed nivolumab for the treatment of metastatic melanoma.

MERCK'S INFRINGEMENT

19. Merck is exploiting the invention of the 994 patent with an anti-PD-1 antibody called pembrolizumab. On information and belief, Merck started developing pembrolizumab after Plaintiffs had made and started testing nivolumab. On September 4, 2014, Merck received approval to sell pembrolizumab in the United States for the treatment of certain patients suffering from metastatic melanoma. According to Merck, pembrolizumab is a PD-1 antibody that works by blocking the PD-1 checkpoint to treat cancer.

20. On information and belief, Merck has known about the 994 patent and has known that the use of pembrolizumab will infringe claims of the 994 patent since July 7, 2015, when the 994 patent was issued by the USPTO and this Complaint was filed.

21. Merck and its affiliates have had knowledge of the family of patents that includes the 994 patent for many years and have instituted legal proceedings seeking to invalidate the corresponding patents in Europe. Merck initiated an opposition proceeding in the European Patent Office on June 20, 2011, against European Patent EP 1 537 878 ("EP 878 patent"), the European counterpart of U.S. Patent Number 8,728,474 (the "474 patent"), the 994 patent's parent patent. Merck made numerous submissions in that opposition proceeding and an oral hearing was held on June 4, 2014. That same day, the panel hearing oral argument rejected Merck's opposition and held the EP 878 patent valid.

22. On May 22, 2014, Merck's European affiliate filed a revocation action in the United Kingdom seeking to revoke the U.K. patent corresponding to the EP 878 patent. BMS has filed a counterclaim alleging infringement by pembrolizumab in that action.

23. On information and belief, Merck received approval from the FDA on September 4, 2014, to market pembrolizumab as a treatment for certain patients with melanoma, and thereafter began selling pembrolizumab for that purpose. Merck's pembrolizumab is especially made for use in infringing the 994 patent and is not a staple article or commodity of commerce suitable for substantial noninfringing use. By making and selling pembrolizumab as a treatment for certain patients with metastatic melanoma, Merck has the specific intent to cause infringement of the 994 patent or, at a minimum, Merck has been willfully blind to the infringement of the 994 patent that will inevitably result.

24. On September 4, 2014, the day Merck received approval to sell its pembrolizumab product in the United States for treatment of melanoma, Plaintiffs filed suit against Merck in this judicial district, asserting the 474 patent, which also claims *inter alia* certain uses of a PD-1 antibody to treat melanoma.

25. On information and belief, Merck has begun, manufacturing, distributing, using, offering for sale, selling, and/or importing in the United States the pembrolizumab antibody product to be prescribed and used for the treatment of metastatic melanoma. Upon information and belief, such pembrolizumab is being used and will be used for the treatment of metastatic melanoma in the United States.

COUNT I: PATENT INFRINGEMENT

26. Plaintiffs incorporate by reference paragraphs 1-25 as if fully set forth herein.

27. A real, immediate, substantial, and justiciable controversy has arisen and now exists between the parties as to whether Merck is infringing the 994 patent.

28. On information and belief, Merck has been aware of the 994 patent since July 7, 2015, when the USPTO issued the 994 patent and Plaintiffs filed this Complaint.

29. On information and belief, Merck is marketing, making, using, selling, offering for sale, and/or importing pembrolizumab in the United States for the treatment of metastatic melanoma. On information and belief, such pembrolizumab is being used for the treatment of metastatic melanoma in the United States. As set forth above, Merck thereby began infringing the 994 patent as of July 7, 2015, including by actively inducing infringement under 35 U.S.C. § 271(b) and as a contributory infringer under 35 U.S.C. § 271(c).

30. Merck's continuing infringement of the 994 patent beginning on July 7, 2015, is deliberate, willful, and in reckless disregard of valid patent claims of the 994 patent.

31. Plaintiffs have been and will continue to be injured by and have been and will continue to suffer substantial damages as a result of Merck's infringement.

JURY DEMAND

Under Federal Rule of Civil Procedure 38, Plaintiffs demand trial by jury of all issues so triable.

PRAYER FOR RELIEF

Wherefore, Plaintiffs respectfully request the following relief:

- (a) entry of a judgment that Defendants infringe and will infringe the 994 patent;
- (b) an award of damages sufficient to compensate Plaintiffs for infringement of the 994 patent, together with pre- and post-judgment interest and costs as fixed by the Court as provided by 35 U.S.C. § 284;
- (c) entry of an order compelling Defendants to compensate Plaintiffs for any ongoing or future infringement of the 994 patent, in an amount and under terms appropriate for the circumstances along with pre and post judgment interest and costs;

(d) entry of an order that Defendants' infringement of the 994 patent has been willful, and increased damages pursuant to 35 U.S.C. § 284;

(e) judgment that this is an exceptional case pursuant to 35 U.S.C. § 285 and an award to Plaintiffs of their reasonable attorney fees, costs, and expenses in this action pursuant to 35 U.S.C. § 285; and

(f) such other relief as the Court may deem just and proper.

Dated: July 7, 2015

Respectfully submitted,

Of Counsel:

FARNAN LLP

Dianne B. Elderkin
Steven D. Maslowski
Matthew A. Pearson
Jason Weil
**AKIN GUMP STRAUSS HAUER & FELD
LLP**
2001 Market Street, Suite 4100
Philadelphia, PA 19103
Tel.: (215) 965-1200
Fax: (215) 965-1210

/s/ Brian E. Farnan
Joseph J. Farnan, Jr. (Bar No. 100245)
Brian E. Farnan (Bar No. 4089)
Michael J. Farnan (Bar No. 5165)
919 N. Market St., 12th Floor
Wilmington, DE 19801
Tel: (302) 777-0300
Fax: (302) 777-0301
farnan@farnanlaw.com
bfarnan@farnanlaw.com
mfarnan@farnanlaw.com

Emily C. Johnson
**AKIN GUMP STRAUSS HAUER & FELD
LLP**
1333 New Hampshire Ave., N.W.
Washington, D.C. 20036
Tel: (202) 887-4000
Fax: (202) 887-4288

*Counsel for Plaintiffs Bristol-Myers Squibb
Co., E. R. Squibb & Sons, L.L.C., Ono
Pharmaceutical Co., Ltd., and Tasuku Honjo.*